natgillin/translations-raw huggingface dataset:
Given the risk of YMDD mutant HBV, maintenance of lamivudine monotherapy is not appropriate in patients with detectable serum HBV DNA at or beyond 24 weeks of treatment (see section 4.4). 
S obzirom na rizik od YMDD mutiranog virusa HBV, održavanje monoterapije lamivudinom nije primjereno u bolesnika s detektabilnim HBV DNK u serumu nakon 24 tjedna liječenja ili dulje od toga (vidjeti dio 4.4).
Sucrose 20 % w/v (4 g/20 ml) Methyl parahydroxybenzoate (E218) 1.5 mg/ml Propyl parahydroxybenzoate (E216) 0.18 mg/ml 
saharoza 20 % m/V (4 g/20 ml) metilparahidroksibenzoat (E218) 1,5 mg/ml propilparahidroksibenzoat (E216) 0,18 mg/ml
This population primarily consisted of children with minimal hepatitis B. A dose of 3 mg/kg once daily (up to a maximum of 100 mg daily) was used in children aged 2 to 11 years and a dose of 100 mg once daily in adolescents aged 12 years and above. 
Djeca od 2 do 11 godina dobivala su dozu od 3 mg/kg jedanput na dan (do maksimalno 100 mg na dan), dok su adolescenti u dobi od 12 godina i više dobivali dozu od 100 mg jedanput na dan.
Keep in touch with your doctor, and don't stop taking Zeffix without your doctor's advice. 
Budite u kontaktu sa svojim liječnikom i nemojte prestati uzimati Zeffix ako Vam to nije savjetovao liječnik.
• In patients with HBeAg positive chronic hepatitis B (CHB) without cirrhosis, treatment should be administered for at least 6-12 months after HBeAg seroconversion (HBeAg and HBV DNA loss with HBeAb detection) is confirmed, to limit the risk of virological relapse, or until HBsAg seroconversion or there is loss of efficacy (see section 4.4). 
• U HBeAg pozitivnih bolesnika s kroničnim hepatitisom B, a bez ciroze, liječenje treba provoditi najmanje 6 - 12 mjeseci nakon potvrđene serokonverzije HBeAg (gubitak HBeAg i HBV DNK uz pojavu HBeAb), kako bi se ograničio rizik od relapsa virusa, odnosno do serokonverzije HBsAg ili do gubitka djelotvornosti (vidjeti dio 4.4).
The most common adverse reactions reported were malaise and fatigue, respiratory tract infections, throat and tonsil discomfort, headache, abdominal discomfort and pain, nausea, vomiting and diarrhoea. 
Najčešće zabilježene nuspojave bile su malaksalost i umor, infekcije dišnih puteva, nelagoda u predjelu grla i tonzila, glavobolja, bol i nelagoda u trbuhu, mučnina, povraćanje i proljev.
Lamivudine is metabolised by both infected and uninfected cells to the triphosphate (TP) derivative which is the active form of the parent compound. 
Lamivudin se metabolizira i u zaraženim i u nezaraženim stanicama u trifosfatni derivat koji je aktivni oblik osnovnog spoja.
Therefore breastfeeding may be considered in breastfeeding mothers being treated with lamivudine for HBV taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. 
Stoga dojenje treba razmotriti u dojilja liječenih lamivudinom zbog HBV-a, pritom uzimajući u obzir prednosti dojenja za dijete i prednosti terapije za majku.
Lamivudine-TP acts as a substrate for the HBV viral polymerase. 
Lamivudin-trifosfat djeluje kao supstrat virusne polimeraze HBV-a.
The incidence of YMDD mutant HBV was similar to that observed in adults, ranging from 19 % at week 52 up to 45 % in patients treated continuously for 24 months. 
Incidencija YMDD tipa virusa bila je slična onoj u odraslih i kretala se od 19% u 52. tjednu do 45% u bolesnika koji su kontinuirano liječeni tijekom 24 mjeseca.
For HIV co-infected patients not requiring anti-retroviral therapy, there is a risk of HIV mutation when using lamivudine alone for treating chronic hepatitis B. 
U bolesnika zaraženih HIV-om kojima nije potrebna antiretrovirusna terapija postoji rizik od mutacije HIV-a pri monoterapiji lamivudinom za liječenje kroničnog hepatitisa B.
For lamivudine-treated patients, the majority of post-treatment ALT elevations occurred between 8 and 12 weeks post-treatment. 
U bolesnika liječenih lamivudinom, porast vrijednosti ALT najčešće je zabilježen u razdoblju između 8 i 12 tjedana nakon liječenja.
3 Abbott Genostics solution hybridisation assay (LLOD < 1.6 pg/ml 4 Chiron Quantiplex assay (LLOD 0.7 Meq/ml) 
Abbott Genostics hibridizacijski test u otopini (LLOD < 1,6 pg/ml) 4. Chiron Quantiplex test (LLOD 0,7 Meq/ml)
In patients with compensated liver disease, these increases in serum ALT were generally not accompanied by an increase in serum bilirubin concentrations or signs of hepatic decompensation. 
U bolesnika s kompenziranom bolešću jetre taj porast serumskih razina ALT obično nije bio popraćen povišenim razinama bilirubina u serumu ili znakovima dekompenzacije jetre.
Zeffix is used to treat long term (chronic) hepatitis B infection in adults. 
Zeffix se primjenjuje za liječenje dugotrajne (kronične) infekcije hepatitisa B u odraslih bolesnika.
A side effect which may show up in blood tests is: 
Druge nuspojave koje se mogu javiti u krvnim pretragama su:
4 Turn the bottle upside down. 
Okrenite bocu naopako.
Co-administration of sorbitol solution (3.2 g, 10.2 g, 13.4 g) with a single 300 mg dose (Adult HIV daily dose) of lamivudine oral solution resulted in dose-dependent decreases of 14%, 32%, and 36% in lamivudine exposure (AUC) and 28%, 52%, and 55% in the Cmax of lamivudine in adults. 
Istodobna primjena otopine sorbitola (3,2 g, 10,2 g, 13,4 g) s jednom dozom od 300 mg (dnevna doza za odrasle osobe s HIV-om) oralne otopine lamivudina rezultirala je o dozi ovisnim smanjenjem od 14%, 32% i 36% u izloženosti lamivudinu (AUC∞) i 28%, 52% i 55% u Cmax lamivudina kod odraslih osoba.
The incidence of adverse reactions and laboratory abnormalities (with the exception of elevations of ALT and CPK, see below) were similar between placebo and lamivudine treated patients. 
Incidencija nuspojava i poremećaja laboratorijskih vrijednosti (s izuzetkom povišenih razina ALT i CK, vidjeti daljnji tekst) bila je podjednaka u bolesnika liječenih lamivudinom i onih koji su dobivali placebo.
Experience in patients with decompensated liver disease Placebo controlled studies have been regarded as inappropriate in patients with decompensated liver disease, and have not been undertaken. 
Iskustvo u bolesnika s dekompenziranom bolešću jetre Placebom-kontrolirana ispitivanja ne smatraju se primjerenima za bolesnike s dekompenziranom bolešću jetre te nisu ni provedena.
Lamivudine serum concentrations (AUC) are increased in patients with moderate to severe renal impairment due to decreased renal clearance. 
Koncentracije lamivudina u serumu (AUC) povišene su u bolesnika s umjerenim do teškim oštećenjem funkcije bubrega zbog smanjenog bubrežnog klirensa.
The rate of overall disease progression in the lamivudine group was higher for subjects with detectable YMDD mutant HBV DNA (23/209, 11 %) compared to those without detectable YMDD mutant HBV (11/221, 5 %). 
Stopa ukupne progresije bolesti u skupini koja je dobivala lamivudin bila je viša u bolesnika s detektibilnim YMDD tipom virusa HBV DNK (23/209, 11%) u odnosu na bolesnike bez detektibilnog YMDD tipa virusa (11/221, 5%).
EU/1/99/114/002 84 tablets 
EU/1/99/114/001 28 tableta EU/1/99/114/002 84 tablete
Zeffix is indicated for the treatment of chronic hepatitis B in adults with: 
Zeffix je indiciran za liječenje kroničnog hepatitisa B u odraslih bolesnika s:
In some patients the development of YMDD mutant HBV can lead to exacerbation of hepatitis, primarily detected by serum ALT elevations and re-emergence of HBV DNA (see section 4.2). 
U nekih bolesnika razvoj YMDD tipa virusa može izazvati egzacerbaciju hepatitisa što se prvenstveno otkriva porastom serumskih razina ALT i ponovnim pojavljivanjem HBV DNK (vidjeti dio 4.2).
If overdose occurs the patient should be monitored and standard supportive treatment applied as required. 
U slučaju predoziranja potrebno je pratiti bolesnika i primjenjivati standardne suportivne mjere.
Nucleoside and nucleotide analogues have been demonstrated in vitro and in vivo to cause a variable degree of mitochondrial damage. 
Analozi nukleozida i nukleotida su u in vitro i in vivo uvjetima pokazali sposobnost uzrokovanja različitih stupnjeva mitohondrijskih oštećenja.
Zeffix should not be taken with any other medicinal products containing lamivudine or medicinal products containing emtricitabine (see section 4.5). 
Zeffix se ne smije uzimati s drugim lijekovima koji sadrže lamivudin ili lijekovima koji sadrže emtricitabin (vidjeti dio 4.5).
Zeffix helps to control your hepatitis B infection. 
Zeffix pomaže u kontroli infekcije hepatitisa B.
In elderly patients the pharmacokinetic profile of lamivudine suggests that normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min (see section 4.2). 
Farmakokinetički profil lamivudina u starijih bolesnika pokazuje da smanjenje funkcije bubrega uslijed normalnog procesa starenja nema klinički značajnog utjecaja na izloženost lamivudinu, osim u bolesnika s klirensom kreatinina < 50 ml/min (vidjeti dio 4.2).
Film-coated tablet: 
Filmom obložene tablete:
In elderly patients, normal ageing with accompanying renal decline has no clinically significant effect on lamivudine exposure, except in patients with creatinine clearance of < 50 ml/min. 
U starijih bolesnika normalno starenje praćeno slabljenjem bubrežne funkcije nema klinički značajnog utjecaja na izloženost lamivudinu, osim u bolesnika s klirensom kreatinina < 50 ml/min.
If you are diabetic, please note that each dose of Zeffix (100 mg = 20 ml) contains 4 g of sucrose. 
Ako ste dijabetičar, uzmite u obzir da svaka doza lijeka Zeffix (100 mg = 20 ml) sadrži 4 g saharoze.
Talk to your doctor if any of these apply to you. 
Razgovarajte sa svojim liječnikom ako se nešto od toga odnosi na Vas.
In an extended treatment study in Asian patients (NUCB3018) the HBeAg seroconversion rate and ALT normalisation rate at the end of the 5 year treatment period was 48 % (28/58) and 47 % (15/32), respectively. 
U produljenom ispitivanju u azijskih bolesnika (NUCB3018) stopa serokonverzije HbeAg nakon 5 godina liječenja iznosila je 48% (28/58), a stopa normalizacije ALT 47 % (15/32).
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Zeffix. 
Ako Vam je liječnik rekao da ne podnosite neke šećere, savjetujte se s liječnikom prije uzimanja lijeka Zeffix.
HBeAg seroconversion 
Serokonverzija
- Baseline ALT  1 x ULN2 - Baseline ALT > 2 x ULN 
- početni ALT ≤ 1 x GGN2 - početni ALT > 2 x GGN
Data are limited on the use of lamivudine in HBeAg negative (pre-core mutant) patients and in those receiving concurrent immunosuppressive regimes, including cancer chemotherapy. 
Ograničeni su podaci o uporabi lamivudina u HBeAg negativnih ("divlji tip" virusa) bolesnika i u bolesnika koji se istodobno liječe imunosupresivnim lijekovima, uključujući i kemoterapiju karcinoma.
• medicines (usually liquids) containing sorbitol and other sugar alcohols (such as xylitol, mannitol, lactitol or maltitol), if taken regularly 
• lijekovi (obično tekućine) koji sadrže sorbitol i druge šećerne alkohole (poput ksilitola,
Diabetic patients should be advised that each dose of oral solution (100 mg = 20 ml) contains 4 g of sucrose. 
Bolesnike s dijabetesom treba upozoriti da svaka doza oralne otopine (100 mg = 20 ml) sadrži 4 g saharoze.
This degree of viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 and most patients had improved markers of liver function and continued to derive clinical benefit. 
Ovaj stupanj viralne supresije je održan (slijedom studije NUC20917) s kombiniranom terapijom tijekom druge godine terapije do 104 tjedna te se kod većine bolesnika poboljšala razina markera jetrene funkcije, kao i nastavak ostvarivanja kliničke dobrobiti.
Data obtained in patients with hepatic impairment, including those with end-stage liver disease awaiting transplant, show that lamivudine pharmacokinetics are not significantly affected by hepatic dysfunction. 
Podaci za bolesnike s oštećenjem jetre, uključujući i one s terminalnim stadijem bolesti koji čekaju transplantaciju, pokazuju da poremećaj funkcije jetre ne utječe značajno na farmakokinetiku lamivudina.
If Zeffix is discontinued, patients should be periodically monitored both clinically and by assessment of serum liver function tests (ALT and bilirubin levels), for at least four months, and then as clinically indicated. 
U slučaju prestanka liječenja lijekom Zeffix, bolesnike treba periodički podvrgavati i kliničkim pregledima i analizi jetrene funkcije (razine ALT i bilirubina u serumu) u razdoblju od najmanje četiri mjeseca, a nakon toga ukoliko je klinički indicirano.
Acute exacerbation of hepatitis has been observed in patients who have discontinued hepatitis B therapy and is usually detected by serum ALT elevations and re-emergence of HBV DNA. 
Akutna egzacerbacija hepatitisa zabilježena je u bolesnika koji su prekinuli terapiju hepatitisa B, a obično se otkriva temeljem porasta serumskih razina ALT i ponovnog pojavljivanja HBV DNK.
Don't take this medicine after the expiry date shown on the bottle and the carton. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na boci i kutiji iza oznake „EXP“.
However, the extent (based on the AUC) of lamivudine absorbed was not influenced, therefore lamivudine can be administered with or without food. 
Međutim, hrana ne utječe na apsorbiranu količinu lamivudina (na temelju AUC) te se lamivudin može uzimati neovisno o obroku.
When lamivudine therapy was continued post transplantation there was reduced graft re-infection by HBV, increased HBsAg loss and on one-year survival rate of 76 - 100 %. 
Kad se liječenje lamivudinom nastavilo i nakon transplantacije došlo je do smanjenja reinfekcije transplantata HBV-om, povećanog gubitka HBsAg, a stopa jednogodišnjeg preživljavanja iznosila je
First dose of Zeffix oral solution * 
Prva doza Zeffix oralne otopine*
• an increase in the level of some liver enzymes (transaminases), which may be a sign of inflammation or damage in the liver. 
• povišene vrijednosti jetrenih enzima (transaminaze), što može upućivati na upalu ili oštećenje jetre
Further results from the trial by YMDD mutant status are summarised in Table 2. 
Ostali rezultati ispitivanja navedeni su u Tablici 2. prema statusu YMDD tipa virusa.
Lamivudine-TP does not interfere with normal cellular deoxynucleotide metabolism. 
Lamivudin-trifosfat ne interferira s normalnim staničnim metabolizmom deoksinukleotida.
The recommended dosage of Zeffix is 100 mg once daily. 
Preporučena doza lijeka Zeffix je 100 mg jedanput na dan.
Side effects thought to be caused by Zeffix 
Nuspojave za koje se smatra da su uzrokovane lijekom Zeffix:
Confirmed HBeAg seroconversion occurred in 47 % (118/252) of subjects treated with lamivudine and 93 % (320/345) of subjects receiving lamivudine became HBV DNA negative (VERSANT [version 1], bDNA assay, LLOD < 0.7 MEq/ml) during the study. 
Serokonverzija HbeAg potvrđena je u 47% (118/252) bolesnika liječenih lamivudinom, a 93% (320/345) bolesnika liječenih lamivudinom postalo je tijekom ispitivanja HBV DNK negativno (VERSANT [verzija 1], bDNK test, LLOD < 0.7 Meq/ml).
Development of YMDD mutant HBV is associated with reduced treatment response in some patients, as evidenced by increased HBV DNA levels and ALT elevations from previous on-therapy levels, progression of signs and symptoms of hepatitis disease and/or worsening of hepatic necroinflammatory findings. 
Razvoj YMDD mutiranog HBV povezan je sa smanjenim terapijskim odgovorom u nekih bolesnika, što se dokazuje povećanim razinama HBV DNK i ALT u odnosu na vrijednosti prije liječenja, progresijom znakova i simptoma hepatitisa i/ili pogoršanjem nalaza nekroze i upale jetre.
The difference in the HBeAg seroconversion rates (HBeAg and HBV DNA loss with HBeAb detection) between placebo and lamivudine was not statistically significant in this population (rates after one year were 13 % (12/95) for placebo versus 22 % (42/191) for lamivudine; p=0.057). 
HbeAb) između placeba i lamivudina u ovoj populaciji nije bila statistički značajna (stope su nakon godinu dana iznosile 13% (12/95) za placebo, a 22% (42/191) za lamivudin; p=0,057).
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON FOR ORAL SOLUTION 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU VANJSKA KUTIJA ZA ORALNU OTOPINU
1 Remove the child-proof bottle cap (A). 
Uklonite sigurnosni zatvarač za djecu (A).
In patients with decompensated liver disease, lamivudine should always be used in combination with a second agent, without cross-resistance to lamivudine, to reduce the risk of resistance and to achieve rapid viral suppression. 
Kod bolesnika s dekompenziranom bolešću jetre, lamivudin se uvijek treba upotrijebiti u kombinaciji s drugim lijekom bez križne rezistencije na lamivudin kako bi se izbjegao rizik rezistencije na lamivudin i kako bi se postigla brza supresija virusa.
For the treatment of patients who are co-infected with HIV and are currently receiving or plan to receive treatment with lamivudine or the combination lamivudine-zidovudine, the dose of lamivudine prescribed for HIV infection (usually 150 mg/twice daily in combination with other antiretrovirals) should be maintained. 
Za liječenje bolesnika koji su istodobno zaraženi i HIV-om te dobivaju ili planiraju dobivati terapiju koja uključuje lamivudin ili kombinaciju lamivudin-zidovudin, ne treba mijenjati dozu lamivudina propisanu za liječenje HIV-infekcije (obično 150 mg/dva puta na dan u kombinaciji s drugim antiretrovirusnim lijekovima).
A very rare side effect (these may affect up to 1 in 10,000 people) is: 
Vrlo rijetke nuspojave (mogu se javiti u do 1 na 10 000 osoba) su:
Progression to cirrhosis occurred in 4/68 (6 %) patients with the YMDD mutant, whereas no patients without the mutant progressed to cirrhosis. 
Progresija u cirozu zabilježena je u 4/68 (6 %) bolesnika s YMDD tipom virusa, dok se to nije dogodilo ni u jednog bolesnika bez YMDD tipa virusa.
After two years of treatment in this study, ALT normalisation and undetectable HBV DNA occurred in 30/69 (43 %) and 32/68 (47 %) patients respectively and improvement in necroinflammatory score in 18/49 (37 %) patients. 
Nakon dvije godine liječenja u toj studiji u 30/69 (43%) bolesnika normalizirane su razine ALT, u 32/68 (47%) razina HBV DNK je bila nemjerljiva, a u 18/49 (37%) bolesnika zabilježeno je i poboljšanje nekroinflamatornog rezultata.
How to take Zeffix 
Kako uzimati Zeffix
It is also only a weak inhibitor of mammalian DNA polymerases alpha and beta. 
Slab je inhibitor alfa i beta DNK polimeraza u sisavaca.
In patients with either HBeAg positive or HBeAg negative CHB, the development of YMDD (tyrosine-methionine-aspartate-aspartate) mutant HBV may result in a diminished therapeutic response to lamivudine, indicated by a rise in HBV DNA and ALT from previous on-treatment levels. 
Klinička rezistencija U HBeAg pozitivnih ili HBeAg negativnih bolesnika s kroničnim hepatitisom B, razvoj mutiranog virusa tipa YMDD (tirozin-metionin-aspartat-aspartat) može dovesti do smanjenog terapijskog odgovora na lamivudin, koji se očituje porastom HBV DNK i ALT u odnosu na prijašnje razine tijekom liječenja.
84 film-coated tablets 
28 filmom obloženih tableta 84 filmom obložene tablete
However, disease progression in YMDD subjects in the lamivudine group was lower than the disease progression in the placebo group (23/209, 11 % versus 38/214, 18 % respectively). 
Ipak, progresija bolesti u bolesnika s YMDD tipom virusa liječenih lamivudinom bila je niža nego u skupini koja je dobivala placebo (23/209, 11%, odnosno 38/214, 18%).
Rhabdomyolysis * In Phase III studies frequency observed in the lamivudine treatment group was not greater than observed in the placebo group 
* U fazi III ispitivanja učestalost zabilježena u skupini liječenoj lamivudinom bila je veća od one u skupini koja ja dobivala placebo
The other ingredients are: sucrose, methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216), citric acid, propylene glycol, sodium citrate, artificial strawberry flavour, artificial banana flavour, purified water. 
Drugi sastojci su: saharoza, metilparahidroksibenzoat (E218), propilparahidroksibenzoat (E216), citratna kiselina, propilenglikol, natrijev citrat, umjetna aroma jagode, umjetna aroma banane, pročišćena voda.
These medicines should not be used with Zeffix: 
Sljedeći se lijekovi ne smiju primjenjivati istovremeno s lijekom Zeffix:
Therapy with Zeffix should be initiated by a physician experienced in the management of chronic hepatitis B. 
4.2 Doziranje i način primjene Terapiju lijekom Zeffix treba započeti liječnik s iskustvom u liječenju kroničnog hepatitisa B.
How much to take The usual dose of Zeffix is one tablet (100 mg lamivudine) once a day. 
Koliku dozu lijeka uzeti Uobičajena doza lijeka Zeffix je jedna tableta (100 mg lamivudina) jedanput na dan.
Viral suppression was maintained (follow-on study NUC20917) with combined therapy during the second year of treatment to week 104 with patients having continued improvement in virologic and biochemical responses. 
Viralna supresija je održavana (na temelju studije NUC20917) s kombiniranom terapijom tijekom druge godine terapije do 104. tjedna te se bolesnicima i virološki i biokemijski odgovor nastavio poboljšavati.
• if you have ever had other types of liver disease, such as hepatitis C 
• ako ste nekad imali drugi tip bolesti jetre, naprimjer hepatitis C • ako ste izrazito pretili (posebno ako ste žena)
In a double-blind study in CHB patients with YMDD mutant HBV and compensated liver disease (NUC20904), with a reduced virological and biochemical response to lamivudine (n=95), the addition of adefovir dipivoxil 10 mg once daily to ongoing lamivudine 100mg for 52 weeks resulted in a median decrease in HBV DNA of 4.6 log10 copies/ml compared to a median increase of 0.3 log10 copies/ml in those patients receiving lamivudine monotherapy. 
U dvostruko slijepom ispitivanju u bolesnika s kroničnim hepatitisom B s YMDD mutiranim HBV-om i kompenziranom bolešću jetre (NUC20904) koji su imali smanjeni virološki i biokemijski odgovor na lamivudin (n=95), dodavanje adefovir dipivoksila u dozi od 10 mg jedanput na dan postojećoj dozi lamivudina od 100 mg tijekom 52 tjedna dovelo je do medijana smanjenja HBV DNK-a od 4,6 log10 kopija/ml u usporedbi s medijanom povećanja od 0,3 log10 kopija/ml u bolesnika koji su primali samo lamivudin.
Patients should be informed that malaise and fatigue have been reported during treatment with lamivudine. 
Bolesnicima treba reći da su tijekom liječenja lamivudinom prijavljeni malaksalost i umor.
Don't take this medicine after the expiry date shown on the carton and blister. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „EXP“.
HBV viral subpopulations with reduced susceptibility to lamivudine (YMDD mutant HBV) have been identified with extended therapy. 
Pri dugotrajnoj terapiji otkrivene su subpopulacije HBV-a sa smanjenom osjetljivošću na lamivudin (YMDD tip virusa).
Hepatitis B infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles). 
Infekcija hepatitisa B širi se spolnim odnosom s nekim tko ima infekciju ili putem zaražene krvi
• a decrease in the number of cells involved in blood clotting (thrombocytopenia). 
• smanjenje broja krvnih stanica važnih za zgrušavanje krvi (trombocitopenija).
If you get any side effects 
Ako primijetite nuspojave
Therefore, the concomitant use of lamivudine with cladribine is not recommended (see section 4.4). 
Stoga se ne preporučuje istodobna primjena lamivudina i kladribina (vidjeti dio 4.4).
Each film-coated tablet contains 100 mg of lamivudine. 
Jedna filmom obložena tableta sadrži 100 mg lamivudina.
There have been reports of mitochondrial dysfunction in infants exposed in utero and/or post-natally to nucleoside analogues. 
Zabilježena je poremećena funkcija mitohondrija u dojenčadi koja su bila izložena analozima nukleozida in utero i/ili po rođenju.
* Zeffix oral solution containing 5 mg/ml lamivudine. 
* Zeffix oralna otopina sadržava 5 mg/ml lamivudina.